Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

UK contract research organization hVIVO (AIM: HVO) is gearing up to test an inhaled antiviral candidate, IN-002, for ...

Inhalon Biopharma, Inc. (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections (ARI), today announced the completion of ...

It’s what’s being called a “Quad-demic,” with cases on the rise for COVID-19, Respiratory syncytial virus (RSV), Influenza, ...

The UKHSA has noted that COVID symptoms have evolved over time. Many individuals now exhibit cold-like symptoms, but others ...

A data point is marked as “insufficient data” if wastewater samples test negative for a virus (because levels are too low to ...

The main treatment for most respiratory illnesses is supportive care, with over-the-counter remedies, Myers said, noting antibiotics are not effective. Care at-home can include: rest, adequate fluid ...

The UK Health Security Agency (UKHSA) issued the urgent alert on Thursday saying illnesses like Norovirus and the flu were on ...

The main signs of HMPV, a highly infectious virus that has apparently swept over regions of northern China in recent weeks, ...

WVU Medicine Princeton Community Hospital reported Thursday that increasing numbers of respiratory illness cases, particularly Influenza type A, is appearing among patients and people coming to the em ...

We’ve seen lots of claims about human metapneumovirus (hMPV) in recent weeks. This explainer looks at what we know about it.